SCHEMBL2743310

SCHEMBL2743310

Cc1ccc(C(=O)CCCC(=O)O)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.78
PDE4B Q07343 1/20 0.66
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
NPC1 O15118 4/20 0.55
RAB9A P51151 3/20 0.55
MEN1 O00255 3/20 0.55
GSK3B P49841 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5849125 0.96 KMT2A (0.78) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9352247 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9352262 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9356308 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9352671 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9352850 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL9352285 0.94 KMT2A (0.75) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL4557000 0.89 KMT2A (0.68) KMT2APDE4BHDAC3HDAC4HDAC1
SCHEMBL16922187 0.88 KMT2A (1.00) KMT2ANPC1RAB9AMEN1GSK3B
Succinic Acid SCHEMBL8467793 0.88 KMT2A (1.00) KMT2ANPC1RAB9AMEN1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118771982-A Method for improving yield of aldol resin in process of producing methylbenzoic acid based on dimethylbenzene oxidation 阿拉善左旗旻利化工有限责任公司 2024-10-15 CN disclosed
CN-118146304-A Polypeptide compound and application of solid tumor diagnosis and treatment 中国人民解放军空军军医大学 2024-06-07 CN disclosed
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 US disclosed
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 US disclosed
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2022-01-06 US disclosed
US-11046706-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2021-06-29 US disclosed
CN-112778117-A Method for synthesizing 4- (4-fluorobenzoyl) butyric acid and analogue thereof in continuous flow microreactor 江苏阿尔法药业有限公司 2021-05-11 CN disclosed
US-20190300541-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2019-10-03 US disclosed
US-10196402-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2019-02-05 US disclosed
EP-3091012-B1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CENTREXION THERAPEUTICS CORP (US) 2018-04-11 EP disclosed
WO-2011073155-A1 NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO disclosed
WO-2011073154-A1 NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO disclosed
US-7115741-B2 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds ALEXION PHARMACEUTICALS, INC. 2006-10-03 US disclosed
US-20030153556-A1 Piperazine and homopiperazine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-08-14 US disclosed
US-6605633-B1 Such as 5-Bromo-2-phenyl-1H-indole-3-butanoic acid FOURNIER INDUSTRIE ET SANTE (FR) 2003-08-12 US disclosed
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 WO disclosed
EP-0412933-B1 Coating compositions CIBA GEIGY AG (CH) 1994-09-14 EP disclosed
US-5183842-A Mixture of ketoacid and amine with film-forming binder, curing CIBA-GEIGY CORPORATION (US) 1993-02-02 US disclosed
US-5128396-A Corrosion inhibiting primers on metallic substrates CIBA-GEIGY CORPORATION (US) 1992-07-07 US disclosed
EP-0412933-A1 Coating compositions CIBA-GEIGY AG (CH) 1991-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300541-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 KMT2A 2280/4885PDE4B 1481/4885HDAC3 908/4885
US-11046706-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 KMT2A 2280/4885PDE4B 1481/4885HDAC3 908/4885
US-20030153556-A1 Piperazine and homopiperazine compounds HAMP, MPL, F2 KMT2A 1823/4885PDE4B 2591/4885HDAC3 821/4885
US-11731981-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 KMT2A 2280/4885PDE4B 1481/4885HDAC3 908/4885
US-10196402-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 KMT2A 2280/4885PDE4B 1481/4885HDAC3 908/4885
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 KMT2A 2280/4885PDE4B 1481/4885HDAC3 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.